We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-10.34%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.59B
AUM Growth
+$58.5M
Cap. Flow
+$270M
Cap. Flow %
17.04%
Top 10 Hldgs %
54.43%
Holding
78
New
26
Increased
17
Reduced
7
Closed
12

Top Buys

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$50.8M
2
ELAN icon
Elanco Animal Health
ELAN
+$41.9M
3
KVUE icon
Kenvue
KVUE
+$41.7M
4
SNY icon
Sanofi
SNY
+$37.1M
5
MRK icon
Merck
MRK
+$21.7M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$51.1M
2
EXEL icon
Exelixis
EXEL
+$36.2M
3
BSX icon
Boston Scientific
BSX
+$32.9M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$32.9M
5
AZN icon
AstraZeneca
AZN
+$22.9M

Sector Composition

Rank Sector Weight
1 Healthcare 85.69%
2 Consumer Staples 2.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
26
Invesco QQQ Trust
QQQ
$455B
$17.9M 1.13%
+50,000
New +$18.5M
MLTX icon
27
MoonLake Immunotherapeutics
MLTX
$1.59B
$16.7M 1.05%
+292,805
New +$16.2M
AGEN
28
Agenus
AGEN
$249M
$15.1M 0.95%
668,237
+422,780
+172% +$12M
ALKS icon
29
Alkermes
ALKS
$8.82B
$15.1M 0.95%
+537,464
New +$15.8M
CYTK icon
30
PUT
Cytokinetics
CYTK
$11B
$14.7M 0.93%
+500,000
New +$16.7M
SNDX icon
31
Syndax Pharmaceuticals
SNDX
$1.84B
$13.7M 0.86%
941,817
-640,474
-40% -$12.1M
INBX
32
DELISTED
Inhibrx, Inc. Common Stock
INBX
$13.6M 0.86%
743,294
-254,989
-26% -$5.34M
YMAB
33
DELISTED
Y-mAbs Therapeutics
YMAB
$12M 0.75%
2,194,278
– –
CLDX icon
34
Celldex Therapeutics
CLDX
$2.77B
$11.7M 0.74%
424,259
+226,501
+115% +$7.1M
GPCR icon
35
Structure Therapeutics
GPCR
$3.49B
$10.2M 0.64%
+202,119
New +$6.51M
CRSP icon
36
PUT
CRISPR Therapeutics
CRSP
$4.58B
$9.08M 0.57%
+200,000
New +$10.3M
SNDX icon
37
CALL
Syndax Pharmaceuticals
SNDX
$1.84B
$8.71M 0.55%
+600,000
New +$11.3M
REPL icon
38
Replimune Group
REPL
$814M
$8.62M 0.54%
503,844
+154,955
+44% +$3.04M
MRNS
39
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$7.93M 0.5%
985,606
+22,987
+2% +$191K
GERN icon
40
Geron
GERN
$911M
$7.85M 0.5%
3,702,546
-1,726,609
-32% -$4.69M
SNDX icon
41
PUT
Syndax Pharmaceuticals
SNDX
$1.84B
$6.53M 0.41%
+450,000
New +$8.51M
SRPT icon
42
CALL
Sarepta Therapeutics
SRPT
$1.66B
$6.19M 0.39%
+51,100
New +$5.78M
DYN icon
43
Dyne Therapeutics
DYN
$4.04B
$6.14M 0.39%
685,133
+244,085
+55% +$2.63M
AXSM icon
44
Axsome Therapeutics
AXSM
$12.4B
$5.62M 0.35%
80,368
-98,874
-55% -$7.39M
CLDX icon
45
PUT
Celldex Therapeutics
CLDX
$2.77B
$5.5M 0.35%
+200,000
New +$6.27M
IMVT icon
46
Immunovant
IMVT
$8.09B
$5.37M 0.34%
+139,885
New +$3.16M
REPL icon
47
PUT
Replimune Group
REPL
$814M
$5.36M 0.34%
+313,100
New +$6.15M
REPL icon
48
CALL
Replimune Group
REPL
$814M
$4.28M 0.27%
+250,000
New +$4.91M
NXTC icon
49
NextCure
NXTC
$17.3M
$3.45M 0.22%
222,655
– –
NCNA
50
NuCana
NCNA
$5.37M
$3.42M 0.22%
1,120
– –
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2023 Portfolio in Review

As of Q3 2023, Sofinnova Investments held 78 positions worth $1.59B, up 3.8% from $1.53B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sofinnova Investments deployed $270M of net new capital in Q3 2023, opening 26 new positions and adding to 17 existing holdings. Its largest new stake was RayzeBio, Inc. Common Stock: 2,419,528 shares worth $53.7M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 98% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Exelixis, an estimated $36.2M trimmed.

  • Sofinnova Investments's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 2,419,528 shares worth $53.7M.
  • Sofinnova Investments added most to Merck in Q3 2023, an estimated $21.7M increase.
  • Sofinnova Investments's biggest Q3 2023 reduction was Exelixis, cutting an estimated $36.2M.
  • Sofinnova Investments fully exited Vertex Pharmaceuticals in Q3 2023, selling an estimated $51.1M.
  • Sofinnova Investments's ten largest holdings make up 54% of its $1.59B portfolio in Q3 2023.
  • Sofinnova Investments opened 26 new positions and closed 12 in Q3 2023.
  • Sofinnova Investments's portfolio value rose 3.8% quarter-over-quarter to $1.59B.

Based on Sofinnova Investments's 13F filing for Q3 2023, filed 14 Nov 2023.